- Home
- MXE vs SER Comparison
MXE vs SER Comparison
Compare MXE & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXE
- SER
- Stock Information
- Founded
- MXE 1990
- SER 2017
- Country
- MXE United States
- SER United States
- Employees
- MXE N/A
- SER N/A
- Industry
- MXE Finance Companies
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- MXE Finance
- SER Health Care
- Exchange
- MXE Nasdaq
- SER Nasdaq
- Market Cap
- MXE 49.7M
- SER 56.5M
- IPO Year
- MXE N/A
- SER 2018
- Fundamental
- Price
- MXE $11.30
- SER $5.65
- Analyst Decision
- MXE
- SER Strong Buy
- Analyst Count
- MXE 0
- SER 2
- Target Price
- MXE N/A
- SER $13.00
- AVG Volume (30 Days)
- MXE 5.8K
- SER 27.0K
- Earning Date
- MXE 01-01-0001
- SER 08-11-2025
- Dividend Yield
- MXE 2.66%
- SER N/A
- EPS Growth
- MXE N/A
- SER N/A
- EPS
- MXE N/A
- SER N/A
- Revenue
- MXE N/A
- SER $130,000.00
- Revenue This Year
- MXE N/A
- SER N/A
- Revenue Next Year
- MXE N/A
- SER N/A
- P/E Ratio
- MXE N/A
- SER N/A
- Revenue Growth
- MXE N/A
- SER N/A
- 52 Week Low
- MXE $8.40
- SER $3.81
- 52 Week High
- MXE $11.51
- SER $10.28
- Technical
- Relative Strength Index (RSI)
- MXE 71.37
- SER 54.65
- Support Level
- MXE $10.92
- SER $4.95
- Resistance Level
- MXE $11.11
- SER $5.63
- Average True Range (ATR)
- MXE 0.16
- SER 0.36
- MACD
- MXE 0.02
- SER 0.03
- Stochastic Oscillator
- MXE 100.00
- SER 86.96
About MXE Mexico Equity and Income Fund Inc. (The)
Mexico Equity and Income Fund Inc is a closed-end, non-diversified management investment company. It maintains an investment objective of long-term capital appreciation through investments in securities, primarily equity, listed on the Mexican Stock Exchange. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.